Eli Lilly Stock Reacts to FDA Liver Failure Report for Foundayo
Eli Lilly's stock initially dropped after the FDA reported a liver failure case linked to its oral obesity drug Foundayo, but shares recovered as analysts downplayed the incident. The company reported strong revenue growth and raised its FY2026 guidance despite pricing pressures and reimbursement challenges.
Topics: FDA GLP-1 drugs obesity drugs pharmaceuticals stock volatility